Drug Trial Radar · NCT07612657
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
May 31, 2028
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- VIVUS LLCIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized background PAH therapy. Participants will be randomly assigned with equal chance to receive either VI-0106 or placebo in a double-blind fashion to assess whether VI-0106 improves outcomes in this population.
Conditions
- Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension (PAH)
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Pulmonary Arterial Hypertension PAH
- Pulmonary Arterial Hypertension WHO Group I
Interventions
VI-0106Drug
Tacrolimus Extended-Release Capsules
PlaceboDrug
Inactive oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 6MWD (6 Minute Walk Distance) at Week 24Time frame: Baseline to Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.